NASDAQ$PLRX
Pliant Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Pliant Therapeutics reported a net loss of $49.7 million for Q4 2024, with increased operating expenses primarily due to the BEACON-IPF Phase 2b/3 clinical trial.
Pliant Therapeutics experienced a net loss of $49.7 million in the fourth quarter of 2024, an increase from the prior-year quarter, mainly driven by higher research and development costs associated with the BEACON-IPF Phase 2b/3 clinical trial, which was discontinued following DSMB recommendation.
- BEACON-IPF Phase 2b trial was discontinued due to an imbalance in unadjudicated IPF-related adverse events, despite early signs of efficacy on FVC.
- Research and development expenses increased to $38.8 million, up from $33.2 million in the prior-year quarter, primarily due to the BEACON-IPF trial.
- General and administrative expenses rose to $14.5 million, from $13.9 million, due to increased employee-related expenses.
- The company reported a net loss of $49.7 million, compared to $41.1 million in the prior-year quarter.
Headline financials
Revenue & EPS history
Pliant Therapeutics · Revenue · Quarterly
$0
Forward guidance
Pliant Therapeutics expects its current cash, cash equivalents, restricted cash, and short-term investments to be sufficient to fund operations for the next 12 months and beyond.
Tailwinds
- Phase 1 trial of PLN-101095 in solid tumors continues to enroll, with interim data expected in Q1 2025.
- PLN-101325 for muscular dystrophies is Phase 1 ready with CTA open in Australia.
- Company expects sufficient funds to cover operations for the next 12 months and beyond.
- Plans to analyze complete data from BEACON-IPF trial to evaluate next steps for bexotegrast's development.
- Appointment of Delphine Imbert as Chief Technical Officer brings extensive product development experience.
Headwinds
- BEACON-IPF Phase 2b trial discontinued due to an imbalance in unadjudicated IPF-related adverse events.
- Discontinuation of BEACON-IPF trial may impact future development of bexotegrast.
- Increased net loss compared to prior year due to higher operating expenses.
- Reduced interest income on short-term investments contributed to higher net loss.
- The company acknowledges various risks and uncertainties related to product development and commercialization, including potential delays in clinical trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-1.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-4.2%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+12.1%
Q3 2020
Best reaction
-11.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.8% | -4.2% | -4.2% | |
| Q3 2025 | +3.3% | +17.6% | -20.9% | |
| Q1 2025 | -1.5% | -2.9% | -1.4% | |
| Q4 2024 | -11.7% | +17.4% | -5.1% | |
| Q3 2024 | -4.5% | -12.0% | -6.4% | |
| Q2 2024 | -6.5% | -9.6% | -1.8% | |
| Q1 2024 | -1.4% | -1.2% | -13.4% | |
| Q4 2023 | -7.8% | -4.8% | -13.4% | |
| Q3 2023 | -8.0% | -12.4% | -2.7% | |
| Q2 2023 | +3.4% | -0.9% | -9.5% | |
| Q1 2023 | +4.2% | -0.0% | +3.0% | |
| Q4 2022 | -10.9% | -9.4% | -17.6% | |
| Q3 2022 | -6.5% | -6.7% | -14.5% | |
| Q2 2022 | +11.9% | +12.6% | +6.2% | |
| Q1 2022 | -6.8% | -1.8% | +40.5% | |
| Q4 2021 | +3.7% | -9.9% | -26.6% | |
| Q3 2021 | -4.0% | -3.2% | -17.9% | |
| Q2 2021 | -6.5% | -12.4% | -15.7% | |
| Q1 2021 | -0.1% | -14.7% | -3.1% | |
| Q4 2020 | +4.6% | +2.5% | -19.9% | |
| Q3 2019 | +12.1% | +9.9% | +21.2% | |
| Q3 2020 | +12.1% | +9.9% | +21.2% | |
| Q2 2020 | -8.5% | -8.2% | -1.2% | |
| Q4 2019 | -8.5% | -8.2% | -1.2% | |
| Q2 2019 | -8.5% | -8.2% | -1.2% | |
| Q1 2020 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro